Dianthus Therapeutics Announces Interim Results from Phase 3 CAPTIVATE Trial of Claseprubart for CIDP
核心洞察
Dianthus Therapeutics will present interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial evaluating claseprubart (搜索) in chronic inflammatory demyelinating polyneuropathy (搜索).
The company has scheduled a conference call and webcast for March 9, 2026 to discuss the clinical data from this pivotal trial.
Claseprubart (搜索) represents a next-generation therapy being developed to transform treatment of severe autoimmune diseases including CIDP (搜索).
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) announced it will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart (搜索) in Chronic Inflammatory Demyelinating Polyneuropathy (搜索) (CIDP (搜索)). The clinical-stage biotechnology company is dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases.
Phase 3 CAPTIVATE Trial Update
The upcoming presentation will focus on interim responder analysis results from Part A of the pivotal Phase 3 CAPTIVATE trial evaluating claseprubart (搜索) in patients with CIDP (搜索). This represents a significant milestone in the development of claseprubart as a potential treatment for this severe autoimmune condition.
Conference Call Details
The live conference call will be accessible by phone through pre-registration, with participants in the question and answer session required to pre-register to receive dial-in numbers and personal PINs. Additionally, the live webcast will be available via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/, with a replay available following the call.
Company Background
Dianthus Therapeutics is based in New York City and Waltham, Massachusetts, and comprises an experienced team of biotech and pharma executives. The company aims to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases through its focus on developing next-generation therapies.